Alle Studien
RekrutierungTherapeutische Bestätigung (Phase III)Interventionell

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with Hereditary Angioedema Type I or II A Pharmacokinetic Subtrial in Adolescent Patients with Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial

This research is an ongoing study to see how safe a new medicine, KVD900, is when taken over a longer period. KVD900 is a tablet designed to treat sudden swelling attacks in people who have a condition called Hereditary Angioedema (HAE) Type 1 or 2. The study involves both adults and teenagers. For teenagers specifically, the researchers are also looking at how their bodies process the medicine. The main goal is to keep an eye on any side effects and understand how patients are generally doing while taking KVD900 for their HAE attacks.

Auf einen Blick

Status
Rekrutierung
Phase
Therapeutische Bestätigung (Phase III)
Sponsor
Kalvista Pharmaceuticals Limited
Einschreibeziel
75
Starten
26 Feb 2024

Worum geht es in dieser Studie?

This study is about a medicine called KVD900, which is being tested for people who have a condition called Hereditary Angioedema (HAE) Type 1 or 2. HAE is a rare genetic condition that causes sudden and unpredictable swelling in different parts of the body, such as the face, hands, feet, tummy, or airways, which can be very painful and sometimes dangerous.

The medicine, KVD900, is an oral tablet, meaning you take it by mouth. It's designed to be used "on-demand" – so when you feel an HAE attack starting. This study is an "open-label extension trial," which means that everyone taking part knows they are receiving the actual study medicine, KVD900. It's an extension because it allows people who have been in previous studies with KVD900 to continue taking it for a longer time.

The main purpose of this study is to closely monitor the safety of KVD900 over a longer period. The researchers want to see if there are any side effects, how often they occur, and if anyone needs to stop taking the medicine because of them. They will also be checking blood test results and general health signs like blood pressure regularly. For teenagers specifically, there's an additional part of the study (called a "subtrial") to understand how their bodies handle and use the medicine.

Wichtige Erkenntnisse

  • This study is testing the long-term safety of KVD900 for HAE Type 1 or 2.
  • KVD900 is a tablet taken at the start of an HAE swelling attack.
  • It's an extension study for people previously in KVD900 trials.
  • Researchers will monitor side effects and overall health.
  • Teenagers will have extra checks to see how their bodies handle the medicine.
  • Participation involves regular visits and health assessments.

Wer könnte berechtigt sein?

To be part of this study, you generally need to be an adult, aged 18 years or older. There might be some specific requirements for teenagers due to the additional part of the study focused on how young bodies process the medicine.

Since this is an "extension" study, it means that you would typically have already taken part in an earlier study for KVD900. This helps the researchers continue to gather long-term information on people who are already familiar with the medicine.

Both males and females can take part. The most important health requirement is that you must have been diagnosed with Hereditary Angioedema Type 1 or Type 2. The study team will check your full medical history and current health to make sure it's safe for you to join.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you 18 years old or older? (Or a teenager specifically asked to join the adolescent subtrial?)
  2. Have you been diagnosed with Hereditary Angioedema Type 1 or Type 2?
  3. Have you previously taken part in a KVD900 study?
  4. Are you able to attend regular study visits and follow instructions?
  5. Are you willing to take the study medicine as directed?
  6. Sind Sie mit Bluttests und körperlichen Untersuchungen einverstanden?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you join this study, you would continue to take the study medicine, KVD900, by mouth when you experience an HAE attack. You would have regular check-ups with the study team. These visits will involve various assessments, including physical examinations, blood tests, and checking your vital signs like blood pressure and heart rate. These checks help the researchers understand how you are responding to the medicine and if there are any safety concerns.

You would also be asked to keep track of your HAE attacks and how well the medicine works for you. The study will look at how quickly your symptoms improve after taking KVD900. The total duration of your participation would depend on the study plan, but because it's an extension study, it's designed to gather long-term information.

Potenzielle Risiken und Vorteile

Taking part in this study may offer potential benefits, such as continued access to a new on-demand treatment for your HAE attacks that might effectively relieve your symptoms. However, like all medicines, KVD900 may have potential side effects. These could include common side effects, or possibly more serious but rare ones, and the study aims to carefully monitor these. You will be told about all known risks before you decide to join. It is very important to remember that participating in any study is completely voluntary, and you have the right to withdraw at any time, for any reason, without affecting your regular medical care.

Standorte (13)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Slowakei
  • —
    Unbestätigt
    Niederlande
  • —
    Unbestätigt
    Italien
  • —
    Unbestätigt
    Bulgarien
  • —
    Unbestätigt
    Ungarn
  • —
    Unbestätigt
    Österreich
  • —
    Unbestätigt
    Deutschland
  • —
    Unbestätigt
    Griechenland
  • —
    Unbestätigt
    Polen
  • —
    Unbestätigt
    Rumänien
  • —
    Unbestätigt
    Frankreich
  • —
    Unbestätigt
    Spanien

Häufige Fragen

What is Hereditary Angioedema (HAE)?

HAE is a rare condition that causes sudden swelling in different parts of your body, which can be painful and sometimes serious.

What is KVD900?

KVD900 is an investigational medicine in tablet form, being studied to treat HAE swelling attacks when they happen.

Is this medicine available to everyone?

No, KVD900 is currently a study medicine and is not yet available as a standard treatment.

Why is this an 'extension' study?

It means people who were in earlier KVD900 studies can continue taking the medicine to gather more information on its long-term safety.

Werde ich wissen, ob ich das echte Medikament bekomme?

Yes, this is an 'open-label' study, so everyone involved knows they are receiving KVD900.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "An Open-label Extension Trial to Evaluate the Long-term Safe… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.